Clinical Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Name: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis — clinical trial record (NCT07672561)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.

Trial Details

NCT Number	NCT07672561
Lead Sponsor	Zhejiang Wenda Pharma Technology LTD.
Conditions	Moderate to Severe Plaque Psoriasis
Enrollment	375 participants
Start Date	2026-03-18
Primary Completion	2026-11-30 (estimated)
Study Completion	2027-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-29